Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy
暂无分享,去创建一个
A. Levis | U. Ricardi | G. Bisi | A. Castiglione | U. Vitolo | A. Filippi | D. Gottardi | M. Bellò | P. Gavarotti | A. Botticella | G. Parvis | B. Botto | M. Bellò
[1] A. LaCasce,et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] M. Baccarani,et al. Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[3] J. S. Júnior,et al. 18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma , 2010, The Journal of Nuclear Medicine.
[4] A. D. Van den Abbeele,et al. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] Michel Meignan,et al. Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.
[6] F. d'Amore,et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Portlock. FDG-PET after two cycles of chemotherapy predicts treatment failure and Progression-free survival in Hodgkin’s lymphoma , 2006 .
[9] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.
[10] N. Mikhaeel,et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] P. Mauch,et al. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M Tubiana,et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. , 1989, Blood.